Jiang Yin Amber Biopharmaceutical Co., Ltd

Amber has its own culture based on “To Conscience, in harmonious balance of knowledge and action”, which inherits one of the brightest methodologies of Chinese philosophy.  The goal is to establish a business entity which can effectively service pharmaceutical and drug discovery communities worldwide.  The core competency is its molecular design technology platform and its capacity to build a brand name in the highly competitive global marketplace.

Amber have developed the molecular design platform---Multiple Dimension Molecular Design (MDMD).  The core concept of MDMD technology is in line with Yi-Jing, which is greatest treasure of the methodology. MDMD is extension and supplement to current molecular design technologies, MDMD can be utilized to conduct the unique structure-structure comparison methodology to evaluate the drugable characters, which is beyond druglikeness characters of chemical compounds.

Ever since its establishment in year of 2010, Amber has been serving the pharmaceutical and drug discovery communities with the unique building blocks collection with over 30000 products in portfolio.  Based on its building block business, Amber has been successfully enlarge its business scope to chemical reagents, intermediates, large scale production,, custom synthesis, compound collection synthesis, trading service, and technical services including molecular design, process development, database services, project based business, etc.

By far, Amber has cumulating an impressive customer base of more than 200 pharmaceutical and drug discovery companies in 14 nations, and through our distributors, the customer base can be easily extended to more than 2000 companies worldwide.  Amber will serve our customers with broad products list and services, with high efficiency and high quality.